SCHEMBL31258404

SCHEMBL31258404

CC(C)(C)OC(=O)C(C)(C)Oc1ccc(Cl)c(N2CCCCC2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 14/20 0.42
DRD3 P35462 1/20 0.41
MAPK1 P28482 2/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
ABCB11 O95342 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
HTR2A P28223 1/20 0.37
PMP22 Q01453 1/20 0.37
PPARA Q07869 1/20 0.37
FBP1 P09467 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24873121 0.80 ALDH1A1 (0.44) GAAHPGDMEN1ALDH1A1KMT2A
SCHEMBL31258385 0.76 PPARA (0.42) DRD3MAPK1HPGDMEN1ALDH1A1
SCHEMBL29699554 0.76 FFAR4 (0.56) FFAR4DRD3MAPK1GAAMEN1
SCHEMBL31258375 0.75 NOX1 (0.41) DRD3MAPK1GAAMEN1ALDH1A1
SCHEMBL23903398 0.72 PPARA (0.66) DRD3MAPK1HPGDMEN1ALDH1A1
SCHEMBL23124713 0.72 FFAR4 (0.53) FFAR4MEN1ALDH1A1KMT2AKDM4E
SCHEMBL23124717 0.72 FFAR4 (0.53) FFAR4MEN1ALDH1A1KMT2AKDM4E
SCHEMBL31258392 0.69 NR1H2 (0.48)
SCHEMBL30093545 0.68 LMNA (0.52) FFAR4MAPK1HPGDMEN1ALDH1A1
SCHEMBL30609810 0.68 BCL9 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240391896-A1 SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION Nantong Jutai Biotech Co., Ltd. (CN) 2024-11-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240391896-A1 SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION BCL9, BCL9L, BCL2L11 FFAR4 3519/4885DRD3 3485/4885MAPK1 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.